



Clinical Effectiveness Group (CEG) Queen Mary University of London 3rd Floor, Abernethy Building, Newark Street, London, E1 2AT

amul.ac.uk/cea

21/08/2025

Re: REGULATION 28: REPORT TO PREVENT FUTURE DEATHS Ref: 29832468

Dear Miss Persaud,

Thank you for your correspondence regarding the tragic death of Mr Hatchett and the associated Regulation 28 report highlighting matters of concern that may help prevent future deaths. We would first like to express our sincere condolences to the family and loved ones of Mr Hatchett.

We have carefully reviewed the concerns raised, specifically regarding a dedicated section for mental health review in clinical templates used for patients with multiple long-term conditions.

We agree that it is important to identify undiagnosed anxiety and depression in those with long term conditions. We do include sections for screening for anxiety and depression within our Long Term Conditions template. There is a dedicated tab within the template to complete validated depression and anxiety screening questionnaires, specifically the PHQ-9 and GAD-7 questionnaires and this has been present within the template for several years. This tab is displayed regardless of previous mental health history, as a way of opportunistically screening for any symptoms of anxiety or depression.

We thank you for raising this important issue. We are committed to supporting general practice in delivering safe, high-quality care and welcome continued dialogue to that end.

Yours sincerely,

Dr Michael O'Hanlon

Clinical Co-Director - Clinical Effectiveness Group (CEG)

Centre for Primary Care Wolfson Institute of Population Health Faculty of Medicine and Dentistry Queen Mary University of London